Pancreatic Cancer

Comprehensive evaluation with accurate diagnosis is the foundation for achieving successful outcomes. That’s why it’s important to seek care from a center that provides academic level care from a multidisciplinary, specialized team of hepatobiliary and pancreatic experts experienced in the accurate diagnosis of pancreatic cancer, as well as other complex gastrointestinal diseases.

Beginning with a thorough evaluation that includes a comprehensive physical exam, personal medical history review and state-of-the-art diagnostic workup, Hoag’s multidisciplinary team of board-certified, fellowship trained pancreatic experts carefully evaluate and pinpoint the nature of the cancer, so the most appropriate personalized treatment options can be employed.

Hoag’s state-of-the-art diagnostic technologies provide our team with the latest modalities in the accurate diagnosis of pancreatic cancer and other disorders. Some of the progressive imaging studies that may be utilized include:

• Volume Rendering Computed Tomography (CT) is the most recent advance in CT technology. Only a few centers in Southern California have this technology, which creates highly accurate 3-D scans of the pancreas. This enables physicians to properly stage the cancer and determine whether the tumor is resectable.

• Endoscopic Ultrasound (EUS) uses an ultrasound device to make images of your pancreas from inside your abdomen. The physician may also collect a sample of cells (biopsy) during EUS.

• Endoscopic Retrograde Cholangiopancreatography (ERCP) uses a dye to highlight the bile ducts in the pancreas, so that an accurate image of the bile duct and pancreatic duct may be obtained. This study is performed to rule out certain diseases of the pancreas and the bile duct. The physician may also insert small tubes (called stents) into the bile duct or the pancreatic duct, if they are obstructed, to relieve the obstruction. Additionally, a tissue sample (biopsy) may be collected during ERCP.

• MRCP is a modified MRI that utilizes specialized software to obtain a composite image of the pancreatic duct and the bile duct from the digital MRI images. This study provides similar information to an ERCP. However, as a diagnostic study, MRCP study is preferred to ERCP since this procedure is not invasive.

• Tumor Markers are used to determine whether certain substances are being released into the blood. Tumor markers are often obtained to assess the probability of a cancer in a patient who has a lesion. While high tumor markers may indicate cancer, they are not definitive since non-cancerous conditions of the pancreas and liver can falsely elevate these tumor markers.

• Diagnostic Laparoscopy is a minimally invasive surgical procedure used to examine internal organs by direct visualization. Small incisions are made in the abdominal wall, and a thin, lighted tube called a laparoscope is inserted. This procedure allows the surgeon to evaluate whether the cancer has spread outside of the pancreas prior to performing surgery. This is an important part of planning for surgery.

• Biopsy is the removal of a sample of tissue for testing. This procedure is performed to definitively diagnose pancreatic cancer, and may involve other methods outside of laparoscopic biopsy, such as endoscopic ultrasound or fine-needle aspiration.

It’s important to note that proper diagnosis and staging of pancreatic cancer is critical to developing a successful treatment plan. That’s why it’s so important to seek proper evaluation and treatment from a healthcare expert experienced in the most advanced pancreatic cancer care.

Innovative Treatment for Pancreatic Cancer

When it comes to pancreatic cancer and other gastrointestinal diseases, Hoag Family Cancer Institute provides a full array of progressive treatment options. As a recognized leader and high-volume provider of innovative gastrointestinal care, Hoag’s multidisciplinary team of digestive disease experts performs some of the most advanced gastrointestinal procedures available in the nation with clinical outcomes that rival national figures.

Expert Care You Can Trust

Hoag Family Cancer Institute provides state-of-the-art, compassionate pancreatic cancer care. Hoag’s committed to accurate diagnosis, combined with progressive therapeutic options enables Hoag patients to achieve some of the highest clinical outcomes in the nation.

To schedule a comprehensive diagnostic evaluation, or a second-opinion consultation with a Hoag pancreatic cancer expert, call us at 949-764-5350.

Pancreatic cancer is the third leading cause of cancer death in both men and women in the United States. In 2025, there were 67,440 new diagnoses and 51,980 deaths. Early disease detection can improve survival rates.

Pancreatic cancer is considered to be an uncommon cancer. The average person only has a 1.6% lifetime risk of developing it, but if someone has a significant family history of pancreatic cancer or a known mutation in a pancreatic cancer susceptibility gene, their risk is likely higher.

As the first in Southern California and one of only a few centers in the U.S., Hoag Family Cancer Institute offers an early detection program to assess individuals at higher risk of developing pancreatic cancer. The purpose of this program is to improve the outcomes for individuals at risk for pancreatic cancer, working to detect early-stage cancer through labs, imaging, and diagnostic testing. As part of the program, individuals will have the option of submitting their de-identified information to be part of a registry, shared by similar organizations in the nation (https://precedestudy.org/). This database will help future clinicians to better understand this complex disease and how to effectively treat and manage it.

Hoag’s Pancreatic Cancer Early Detection Clinic is led by a multidisciplinary team of specialists including a nurse practitioner, genetic counselors, gastroenterologists and pancreatic surgeons. Together, this team supports all aspects of care, collaborating with other physician specialists, to ensure an individual’s risk is accurately assessed and managed.

Do I qualify?

Since pancreatic cancer is a rare cancer, Hoag’s PCDC aims to enroll and screen those at increased risk for pancreatic cancer at this time. This includes individuals with a strong family history of pancreatic cancer, or those with mutations in certain genes. Patients eligible for this program are those with confirmed germline pathogenic or likely pathogenic variants in a pancreatic cancer gene (e.g. ATM, BRCA1, BRCA2, CDKN2A, PALB2, STK11, etc.). Individuals with variants of unknown/uncertain significance in these genes do not qualify. Individuals can also qualify for Hoag’s PCDC based on family history (no gene mutation required) in any of the following ways:

• 1 first degree relative with pancreatic ductal adenocarcinoma (PDAC) diagnosed at or before age 45

• 2 relatives (any relation) on the same side of the family with PDAC diagnosed at any age

Screening in this program begins at age 50 unless the individual has a CDKN2A mutation (start at age 40), a STK11 mutation (start at age 35), or has a relative who was diagnosed with PDAC at a young age (start 10 years younger than the earliest PDAC in the family). Individuals younger than 50 who do not meet these exceptions do not qualify at this time but will qualify at age 50.

What happens in the program?

The clinic runs at the Hoag Family Cancer Institute in Newport Beach. Someone enrolled in the program can expect annual office visits with our nurse practitioner. The nurse practitioner will enter appropriate orders (blood work, abdominal MRI, endoscopic ultrasound, etc.) for the individual to complete after the visit. The individual will also meet with a genetic counselor during their office visit every other year to review their family history and any new genetic information.

If you have any questions, would like to determine whether or not you are eligible, or want to schedule an initial appointment, please contact the Hoag’s Pancreatic Cancer Detection Clinic at 949-764-7475.

When it comes to pancreatic cancer and other gastrointestinal conditions, expert evaluation is vital to accurately diagnose pancreatic cancer and then determine the best course of treatment for the individual patient.

At Hoag, our multidisciplinary team of experts work together to thoroughly review and determine the pancreatic cancer treatment option suited to each individual patient.

The team then carefully tailors a personalized treatment plan to effectively achieve the best possible outcome for the patient. This emphasis on a collaborative, comprehensive approach to patient-centered care is why Hoag patient outcomes rank are among the nation’s best.

Once pancreatic cancer is diagnosed, important staging tests (such as diagnostic laparoscopic examination) are performed to determine if the cancer has spread, and if so, to what extent. The type of treatment recommended depends upon the stage of the cancer and may include options such as:

Pancreatic Cancer Surgery

Pancreatic cancer treatment options depends on the type of tumor and where in the pancreas the tumor is located.

Innovative surgical treatment is offered for patients with an adenocarcinoma of the pancreas since this tumor is associated with a poor outcome if not completely eradicated by surgery. However, in patients with less aggressive cancers, surgical treatment, including minimally invasive approaches, may be indicated in selected cases. Hoag’s philosophy is to always emphasize organ preservation whenever possible.

When it comes to advanced surgical care, the Hoag surgical team performs more complex pancreatic surgeries than any other surgical program in Southern California including state-of-the-art procedures that may not available at most centers. Being a high-volume pancreatic cancer surgical program enables the gastrointestinal experts at Hoag to achieve a technical skill level not all facilities can match.

Some of the advanced surgical options for treating tumors of the pancreas include:

• The Whipple Operation involves resection (removal) of the head of the pancreas, a portion of the bile duct, the gallbladder and the duodenum. Occasionally, a portion of the stomach may also be removed. The Whipple Operation is often used to treat patients with adenocarcinoma of the pancreas, although it may be recommended for some patients with benign disorders such as chronic pancreatitis and benign tumors of the head of the pancreas.

• Central Pancreatectomy may be recommended for patients who have low-grade malignant or benign tumors in the neck of the pancreas. Removal of tumors in this area often requires removing a large portion of the pancreas. However, Hoag offers a highly specialized surgical procedure that removes only the tumorous portion of the neck of the pancreas, thereby preserving the head, body and tail of the pancreas.

• Laparoscopic/Robotic-Assisted Pancreatectomy is a minimally invasive surgical procedure where the body and tail of the pancreas is removed along with the spleen. This procedure is most frequently performed in patients with adenocarcinoma of the pancreas. However, Hoag routinely provides laparoscopic spleen-preserving pancreatectomy for patients with cystic tumors and neuroendocrine tumors.

• Duodenum Preserving Pancreatic Head Resection is offered primarily to patients with chronic pancreatitis, although the procedure may also be offered to some patients with neuroendocrine tumors who would otherwise require a Whipple Operation. In this procedure, the head of the pancreas is removed while preserving the bile duct and duodenum (the first part of the intestine). Hoag is one of the few centers in the United States to offer this innovative surgical procedure.

• Enucleation of pancreatic islet cell tumors is surgical procedure that carefully removes islet cell tumors without removing any pancreatic tissue. Pancreatic islet cell tumors (also called neuroendocrine tumors) are small tumors found on the surface of the pancreas. Hoag surgeons have developed a laparoscopic technique for enucleation of pancreatic islet cell tumors, which provides a number of benefits to patients including a faster recovery and return to daily activities.

Locally Advanced Pancreatic Cancer

Locally advanced pancreatic cancer describes pancreatic cancer that involves other structures near the pancreas. The most frequently involved structure is the portal vein.

At Hoag, our expert team of hepatobiliary surgeons is experienced in advanced surgical techniques that allow the cancer to be removed with reconstruction of the portal vein utilizing an innovative vein graft procedure. In addition to the portal vein, other adjacent structures can also be removed, if necessary, and reconstructed using similar advanced surgical techniques.

It’s important to note that often patients with pancreatic cancer are told that their cancer is not resectable, or that they may not be a candidate for surgery. At Hoag, our academic-level hepatobiliary surgeons have extensive experience and training in complex pancreatic surgery, and can often resect locally advanced tumors due to their expertise, which is why it’s important to seek out a second opinion.

Non-Surgical Treatment Options

In addition to progressive surgical options, Hoag also provides the full array of innovative non-surgical options for treating pancreatic cancer, including:

Radiation therapy may be recommended before or after cancer surgery, often in combination with chemotherapy. Combination radiation therapy and chemotherapy may also be utilized in cases where a cancer cannot be treated surgically.

• Chemotherapy uses drug therapy to help destroy cancer cells. Chemotherapy is often combined with radiation therapy to treat cancer that has spread beyond the pancreas to nearby organs, but not to distant regions of the body. This combination chemotherapy-radiation therapy protocol may also be used after surgery to reduce the risk that pancreatic cancer may recur. In individuals with advanced pancreatic cancer, chemotherapy may be used alone or it may be combined with targeted drug therapy.

• Targeted therapy uses drugs that attack specific abnormalities within cancer cells. For example, the targeted drug erlotinib (Tarceva) blocks chemicals that signal cancer cells to grow and divide. This drug is usually combined with chemotherapy for use in people with advanced pancreatic cancer.​

• Clinical Trials play a significant role in gastrointestinal cancer treatment. Hoag physicians participate in a variety of clinical trials in order to bring advanced care to Hoag pancreatic cancer patients.

The Most Advanced Pancreatic Cancer Treatment Options Are Available at Hoag

When it comes to seeking out the most advanced pancreatic cancer care, there is no longer any need to travel long distances. Hoag Family Cancer Institute offers the latest in state-of-the-art diagnosis and leading-edge treatment options that may not be readily available at other centers, including resection of advanced pancreatic cancers, as well as participation in clinical trials that helps to bring advanced care to even more patients.

Perhaps the most distinguishing aspect of Hoag’s advanced treatment of pancreatic conditions is that in each and every case, treatment is always specifically tailored to the meet the unique needs of the individual patient.

Expert Care You Can Trust

Hoag Family Cancer Institute provides state-of-the-art, compassionate pancreatic cancer care. Hoag’s committed to accurate diagnosis, combined with progressive therapeutic options enables Hoag patients to achieve some of the highest clinical outcomes in the nation.

To schedule a comprehensive diagnostic evaluation, or a second-opinion consultation with a Hoag pancreatic cancer expert, call us at (949) 764-5350.

Hoag is committed to leading the way in state-of-the-art technologies and advanced treatment options. Part of this commitment includes clinical research with the goal of helping patients live longer, healthier lives. Through carefully planned clinical trials, researchers evaluate the safety and effectiveness of new ways to diagnose, treat and prevent diseases or conditions. Treatments studied in clinical trials might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. View clinical trials for pancreatic cancer here.